A retrospective cohort study of the efficacy of immune checkpoint inhibitors in any line of treatment in patients with advanced non-small-cell lung cancer in Italy
Latest Information Update: 06 Sep 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Sep 2021 New trial record
- 01 Sep 2021 Results published in the Lung Cancer